MedKoo Cat#: 522711 | Name: GW590735
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GW590735 is a potent and selective agonist of PPARα with an EC50 value of 4 nM for the expression a GAL4-responsive reporter gene and at least 500-fold selectivity versus PPARγ and PPARδ. GW590735 significantly increased HDL cholesterol, decreased LDL and VLDL cholesterol, and significantly reduced triglycerides. Maximal increases in HDL cholesterol were 37%, 53%, and 84% with fenofibrate, torcetrapib, and GW590735, respectively.

Chemical Structure

GW590735
GW590735
CAS#343321-96-0 (free acid)

Theoretical Analysis

MedKoo Cat#: 522711

Name: GW590735

CAS#: 343321-96-0 (free acid)

Chemical Formula: C23H21F3N2O4S

Exact Mass: 478.1174

Molecular Weight: 478.49

Elemental Analysis: C, 57.73; H, 4.42; F, 11.91; N, 5.85; O, 13.37; S, 6.70

Price and Availability

Size Price Availability Quantity
50mg USD 550.00 2 Weeks
100mg USD 950.00 2 Weeks
200mg USD 1,650.00 2 Weeks
500mg USD 3,650.00 2 Weeks
1g USD 4,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
Synonym
GW590735; GW-590735; GW 590735
IUPAC/Chemical Name
2-methyl-2-(4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazole-5-carboxamido)methyl)phenoxy)propanoic acid
InChi Key
ILUPZUOBHCUBKB-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H21F3N2O4S/c1-13-18(33-20(28-13)15-6-8-16(9-7-15)23(24,25)26)19(29)27-12-14-4-10-17(11-5-14)32-22(2,3)21(30)31/h4-11H,12H2,1-3H3,(H,27,29)(H,30,31)
SMILES Code
CC(OC1=CC=C(CNC(C2=C(C)N=C(C3=CC=C(C(F)(F)F)C=C3)S2)=O)C=C1)(C)C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Certificate of Analysis
Safety Data Sheet (SDS)
Biological target:
A potent and selective agonist of PPARα.
In vitro activity:
GW590735, at a concentration of 4 nM, significantly reduced NAD(P)H levels from 196 ± 5% in the vehicle control-treated CI-deficient fibroblasts to 118 ± 4% in the GW590735-treated CI-deficient fibroblasts (p < 0.001, Fig. 1H). Reference: Life Sci. 2022 Jul 1;300:120571. https://pubmed.ncbi.nlm.nih.gov/35469913/
In vivo activity:
However, all three genes showed significant increases in expression ranging from 5- to 10-fold in liver tissue (Figure 6C). Taken together with the luciferase assay, these data suggest that the PPARα pathway can be successfully induced by GW590735 in the liver, but not the retina, of non-diabetic mice. Reference: J Clin Med. 2020 Dec 31;10(1):126. https://pubmed.ncbi.nlm.nih.gov/33396512/
Solvent mg/mL mM
Solubility
DMF 30.0 62.70
DMSO 30.0 62.70
Ethanol 30.0 62.70
PBS (pH 7.2) 0.3 0.52
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 478.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Frambach SJCM, de Haas R, Smeitink JAM, Russel FGM, Schirris TJJ. Restoring cellular NAD(P)H levels by PPARα and LXRα stimulation to improve mitochondrial complex I deficiency. Life Sci. 2022 Jul 1;300:120571. doi: 10.1016/j.lfs.2022.120571. Epub 2022 Apr 22. PMID: 35469913. 2. Bisgaier CL, Oniciu DC, Srivastava RAK. Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease. J Cardiovasc Pharmacol. 2018 Jul;72(1):3-10. doi: 10.1097/FJC.0000000000000580. PMID: 29621036; PMCID: PMC6039382. 3. Enright JM, Zhang S, Thebeau C, Siebert E, Jin A, Gadiraju V, Zhang X, Chen S, Semenkovich CF, Rajagopal R. Fenofibrate Reduces the Severity of Neuroretinopathy in a Type 2 Model of Diabetes without Inducing Peroxisome Proliferator-Activated Receptor Alpha-Dependent Retinal Gene Expression. J Clin Med. 2020 Dec 31;10(1):126. doi: 10.3390/jcm10010126. PMID: 33396512; PMCID: PMC7794763.
In vitro protocol:
1. Frambach SJCM, de Haas R, Smeitink JAM, Russel FGM, Schirris TJJ. Restoring cellular NAD(P)H levels by PPARα and LXRα stimulation to improve mitochondrial complex I deficiency. Life Sci. 2022 Jul 1;300:120571. doi: 10.1016/j.lfs.2022.120571. Epub 2022 Apr 22. PMID: 35469913. 2. Bisgaier CL, Oniciu DC, Srivastava RAK. Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease. J Cardiovasc Pharmacol. 2018 Jul;72(1):3-10. doi: 10.1097/FJC.0000000000000580. PMID: 29621036; PMCID: PMC6039382.
In vivo protocol:
1. Enright JM, Zhang S, Thebeau C, Siebert E, Jin A, Gadiraju V, Zhang X, Chen S, Semenkovich CF, Rajagopal R. Fenofibrate Reduces the Severity of Neuroretinopathy in a Type 2 Model of Diabetes without Inducing Peroxisome Proliferator-Activated Receptor Alpha-Dependent Retinal Gene Expression. J Clin Med. 2020 Dec 31;10(1):126. doi: 10.3390/jcm10010126. PMID: 33396512; PMCID: PMC7794763.
1: Hansen MK, McVey MJ, White RF, Legos JJ, Brusq JM, Grillot DA, Issandou M, Barone FC. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice. J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):196-202. doi: 10.1177/1074248410362891. Epub 2010 Mar 23. PubMed PMID: 20332533. 2: Velkov T, Rimmer KA, Headey SJ. Ligand-enhanced expression and in-cell assay of human peroxisome proliferator-activated receptor alpha ligand binding domain. Protein Expr Purif. 2010 Apr;70(2):260-9. doi: 10.1016/j.pep.2009.09.012. Epub 2009 Sep 24. PubMed PMID: 19782138. 3: Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab. 2009 Sep;94(9):3594-601. doi: 10.1210/jc.2009-0111. Epub 2009 Jun 16. PubMed PMID: 19531592. 4: Billin AN. PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert Opin Investig Drugs. 2008 Oct;17(10):1465-71. doi: 10.1517/13543784.17.10.1465 . Review. PubMed PMID: 18808307. 5: Risérus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheeseman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O'Rahilly S, Sutton P, Willson T, Hassall D, Frayn KN, Karpe F. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes. 2008 Feb;57(2):332-9. Epub 2007 Nov 16. PubMed PMID: 18024853. 6: Sierra ML, Beneton V, Boullay AB, Boyer T, Brewster AG, Donche F, Forest MC, Fouchet MH, Gellibert FJ, Grillot DA, Lambert MH, Laroze A, Le Grumelec C, Linget JM, Montana VG, Nguyen VL, Nicodème E, Patel V, Penfornis A, Pineau O, Pohin D, Potvain F, Poulain G, Ruault CB, Saunders M, Toum J, Xu HE, Xu RX, Pianetti PM. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J Med Chem. 2007 Feb 22;50(4):685-95. Epub 2007 Jan 23. PubMed PMID: 17243659.